Vogt-Koyanagi-Harada Disease

  title={Vogt-Koyanagi-Harada Disease},
  author={Francisco Max Damico and Szilard Kiss and Lucy H Young},
  journal={Seminars in Ophthalmology},
  pages={183 - 190}
Vogt-Koyanagi-Harada disease (VKH) is a multisystem autoimmune disorder principally affecting pigmented tissues in the ocular, auditory, integumentary and central nervous systems. Patients are typically 20 to 50 years old and have no history of either surgical or accidental ocular trauma. Pigmented races are more commonly affected. Depending on revised diagnostic criteria, the disease is classified as complete, incomplete or probable based on the presence of extraocular findings (neurological… 
Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment
Vogt-Koyanagi-Harada syndrome: a rheumatologic perspective
The success in preserving the vision of VKH syndrome patients hinges on early diagnosis and aggressive treatment that includes immunomodulatory therapy, and as a result ophthalmologists are increasingly referring such patients to specialists.
Vogt-Koyanagi-Harada disease
Vogt-Koyanagi-Harada syndrome.
Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia
Ocular coherence tomography (OCT) has largely replaced other imaging modalities in the diagnosis of VKH and SO by revealing exudative retinal detachments and choroidal thickening in the acute stage and demonstratingChoroidal thinning in the chronic stage.
Vogt-Koyanagi-Harada Syndrome
Vogt-Koyanagi-Harada (VKH) syndrome is a bilateral granulomatous panuveitis characterized by serous retinal detachments and a spectrum of extraocular findings. The disease is thought to arise from a
Vogt–Koyanagi–Harada Disease
Vogt–Koyanagi–Harada disease is a bilateral granulomatous panuveitis associated to extraocular manifestations such as poliosis, vitiligo, alopecia, central nervous system, and auditory signs.
Management of ocular complications of Vogt-Koyanagi-Harada syndrome
Use of ocular invasive treatment modalities in Vogt-Koyanagi-Harada Syndrome only if the disease progression cannot be controlled is recommended, and if systemic medications fail to stop the progression of the disease activity, subtenon injections may be considered before intraocular treatmentmodalities.
Vogt-Koyanagi-Harada syndrome presenting with bilateral optic disc swelling and leptomeningeal enhancement
A case of VKH is described in an elderly Polish-Australian distinguished by prominent bilateral disc swelling rather than uveitis and marked leptomeningeal enhancement on MRI which led to extensive investigation including brain biopsy.


Vogt-Koyanagi-Harada disease.
  • R. Read
  • Medicine
    Ophthalmology clinics of North America
  • 2002
In this report the clinical features of the syndrome will be surveyed, and two cases focusing on neurological aspects will be studied.
Tyrosinase Family Proteins Are Antigens Specific to Vogt-Koyanagi-Harada Disease1
It is found that exposure of lymphocytes from patients with VKH disease to peptides (30-mer) derived from the tyrosinase family proteins led to significant proliferation of the lymphocytes.
Echographic features of the Vogt-Koyanagi-Harada syndrome.
Standardized echography should be considered an important diagnostic tool in VKH syndrome, especially when visualization of the fundus is poor or when clinical presentation is atypical.
Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus.
Evidence of T and B lymphocytes in these uveal tissues indicates that the inflammation remained active even at the convalescent stage of Vogt-Koyanagi-Harada disease.
Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats.
Lewis rats developed an ocular and extraocular inflammatory disease 12 days after immunization with TRP1 or TRP2 that was characterized clinically by the infiltration of inflammatory cells and accumulation of massive fibrin in the anterior and posterior chambers of the eye.
Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.
The early, aggressive use of systemic corticosteroids in patients with Vogt-Koyanagi-Harada syndrome and a gradual tapering of drug dosage for 6 months after presentation are recommended.